Anxiety symptoms in patients with Mayer-Rokitansky-Küster-Hauser syndrome: a cross-sectional study

Shuang Song¹, Na Chen¹, Yan-Ping Duan², Jia Kang¹, Shan Deng¹, Hong-Xin Pan³, Lan Zhu¹

¹Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; ²Department of Psychology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; ³Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Shenzhen University, Luohu People’s Hospital, Shenzhen, Guangdong 518001, China.

Abstract

Background: As a congenital malformation that results in infertility and an inability to have vaginal intercourse, Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome places a considerable psychological burden on patients, which results in anxiety symptoms. However, only single case studies or a few small to medium-sized cross-sectional studies were identified to focus on anxiety symptoms in MRKH patients. Thus, the aim of this study was to explore the status of anxiety symptoms and the related factors in patients with MRKH syndrome.

Methods: This cross-sectional study involving 141 patients with MRKH syndrome and 178 healthy women was conducted from January 2018 to December 2018. All participants were required to complete a demographic questionnaire and the Generalized Anxiety Disorder 7-item scale (GAD-7), Patient Health Questionnaire-9, Eysenck Personality Questionnaire-Revised, Short Scale for Chinese, and Chinese Version of the Female Sexual Function Index. The main outcome was the anxiety symptoms measured by the GAD-7. Main outcome was compared between the MRKH syndrome group and the healthy control group. Then, we explored the related factors by comparing patients with and without anxiety symptoms.

Results: Of the respondents, 24.1% experienced moderate to severe anxiety symptoms. Patients with MRKH syndrome manifested more severe anxiety symptoms than healthy women. Negative self-evaluation of femininity (odds ratio [OR] 2.706, 95% confidence interval [CI] 1.010–7.247), neurotic personality traits (OR 1.175, 95% CI 1.029–1.327), and coexisting depressive symptoms (OR 4.422, 95% CI 1.498–13.049) were more prevalent in anxious patients.

Conclusion: The findings stress the importance of anxiety symptom screening in MRKH patients and identify patients at risk of anxiety symptoms, providing a possible basis for future intervention.

Keywords: MRKH syndrome; Anxiety; Risk factors

Introduction

Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is a rare disease with an estimated incidence of 1 per 4000 to 5000 females.¹ Due to an embryonic developmental aberration of the Mullerian duct, the uterus and the upper two-thirds of the vagina are absent in patients with MRKH syndrome. Patients diagnosed with this condition, therefore, experience sexual intercourse difficulty and infertility because of the malformation. MRKH syndrome is often associated with malformations in renal and skeletal systems. Therefore, this disease is typically classified as type 1, which is characterized by normal development of other systems, and type 2, with abnormal renal and/or skeletal malformations.²

Anxiety is a common but often neglected emotional expression in patients in medical settings,³ with patients with MRKH syndrome being no exception. A large body of literature reports that a diagnosis of MRKH syndrome has a variety of psychological effects on patients, including depression, self-esteem and body image disturbances, feelings of incompleteness, and doubts about female identity.⁴⁻⁶ However, very little is known about the anxiety status of this population. Only a few case studies have reported the patient’s anxious feelings. After diagnosis, patients might feel anxiety about their femininity, physical image, and infertility.⁷⁻⁸ A few studies enrolling relatively small samples have taken anxiety symptoms as one of the outcome measures, but without further analysis of the potential risk factors.

Access this article online

Quick Response Code: www.cmj.org
DOI: 10.1097/CM9.0000000000000648

Correspondence to: Dr. Lan Zhu, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
E-Mail: zhu_julie@vip.sina.com

© 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-N-D), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2020;133(4) Received: 19-09-2019 Edited by: Li-Min Chen

388
Thus, to fill this gap in the current literature, our study aimed to investigate the incidence of anxiety symptoms and identify factors associated with anxiety symptoms in a large sample of MRKH patients.

Methods

Ethical approval

The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of the Peking Union Medical College Hospital (PUMCH) (No. S-K471). Informed written consent was obtained from all patients before their enrollment in this study.

Study participants

The study was conducted from January 2018 to December 2018 at the Center of Obstetrics and Gynecology of PUMCH. All women with a confirmed diagnosis of MRKH syndrome who had been seen in our clinic within the previous year and were over 16 years old were invited to join the study. Patients reporting pre-existing psychiatric disorders were excluded from our study. The female controls were age-matched women without symptoms of somatic disorders recruited from the Physical Examination Center of this hospital.

Study design

This study was a web-based cross-sectional survey. An estimated sample size of 120 cases was calculated. Eligible patients and female controls were given an introductory letter explaining the purpose and voluntary nature of the survey, attached to which was a link to the online questionnaire. If participants consented to participate in this study, they signed the informed consent form, completed the questionnaire through the attached link and submitted the survey to the webserver.

Questionnaire

The initial questionnaire gathered data pertaining to the patient’s demographic background and medical history. The demographic background consisted of age, religious belief, education level, family income level, marital status, and the state of sexual partner and offspring. Moreover, self-evaluation of patient’s family relationship and supports got from family were also collected in the questionnaire. Medical history part inquired about the type of disease, post-diagnosis period, and treatment received. Then, the Chinese version of the Generalized Anxiety Disorder 7-item scale (GAD-7) was used to assess the anxiety states of the participants. Though initially designed for detecting generalized anxiety disorder, the GAD-7 has also performed well in detecting other common anxiety disorders, such as panic disorder, social anxiety disorders, and post-traumatic stress disorder. It is used in primary care and has been validated in a general population sample. Therefore, growing evidence supports that the GAD-7 can be used as a self-report anxiety measure for initial screening. The Chinese version has been validated on outpatients in Chinese general hospitals. It comprises seven items, with each item scored from 0 to 3. Anxiety symptoms can be grouped as minimal (0–4), mild (5–9), moderate (10–14), or severe (15–21) based on the GAD-7 total score. Using a score of 10 as a cut-off, the sensitivity and specificity of the GAD-7 for diagnosing anxiety disorder are 0.86 and 0.95, respectively. Hence, the participants were divided into anxiety and non-anxiety groups based on a cut-off score of 10.

In addition to the GAD-7 to evaluate anxiety symptoms, other validated measurements and questions related to the participants’ psychological states were used: (1) the Patient Health Questionnaire-9 is a widely used depression screening instrument validated in the general population. It is a nine-item self-administered questionnaire whose questions reflect all nine criteria upon which the diagnosis of Diagnostic and Statistical Manual of Mental Disorders, 4th edition depressive disorder is based. Using the summed-item scoring method, it was determined that a cut-off point of ≥10 had a pooled sensitivity of 0.77 and a specificity of 0.85 for screening depression symptoms, representing satisfactory diagnostic performance for screening purposes. (2) The Eysenck Personality Questionnaire-Revised, Short Scale for Chinese is a personality-measuring tool with satisfactory reliability and validity in the general population over 16 years old. Extraversion (E), neuroticism (N), psychoticism (P), and lie inventory (L) were the four sub-scales administered. (3) The Chinese Version of the Female Sexual Function Index was used to assess sexual function in patients who had received non-surgical or surgical intervention for the construction of a neovagina and had been sexually active in the past 4 weeks. Based on epidemiological research with Chinese women, patients with FSFI total scores less than 23.45 were defined as having sexual dysfunction. Related questions such as “Do you think you possess good femininity?” and “What’s your plan for generating offspring?” were also added to the questionnaire. These questions aimed to evaluate patients’ attitudes towards their female identity and parenthood, which are reported to be affected after a diagnosis of MRKH syndrome.

Statistical analysis

The differences with respect to the results of GAD-7 between the MRKH patients and healthy women were analyzed based on one-way analysis of covariance, with the demographic variables of age, educational level and family income as covariates. Then, patients were divided into anxiety and non-anxiety groups based on the GAD-7 score. Univariable analysis was used to assess variables associated with the outcomes. Factors with a P < 0.1 in the univariable analysis were then used in the stepwise multiple logistic regression analysis to identify the potential risk factors for anxiety symptoms in patients with MRKH syndrome. The descriptive statistics are presented as the mean values ± standard deviations (SD) or medians and interquartile ranges for continuous variables and frequencies for categorical variables. Pearson χ² and Fisher’s exact tests were used to analyze categorical variables, while independent samples t tests or Mann-
Whitney U tests were performed to analyze continuous variables. \( P < 0.05 \) was considered statistically significant. For pairwise comparisons, the Bonferroni-adjusted \( P \) value was calculated. All statistical analyses were performed with the IBM® SPSS® 21.0 statistical package (SPSS Inc., Chicago, IL).

**Results**

We distributed questionnaires to 218 eligible patients and received 141 valid responses, resulting in a response rate of 64.7%. By advertisement-based recruitment, we received 178 valid questionnaires from healthy women. Table 1 displays the demographic characteristics of the patients. The mean age of the patients was 25.8 ± 4.6 years, and the average post-diagnosis period was 7.7 ± 4.5 years. 92 patients (65.2%) were diagnosed with type 1 MRKH syndrome while 49 patients (34.8%) were diagnosed with type 2 MRKH syndrome. Nearly half of the patients (67/141, 47.5%) had received non-surgical dilation, and nearly one-third of the participants (41/141, 29.1%) had received vaginoplasty surgery, 37 by the biomaterial graft method, and four by the peritoneal method. The remaining 33 patients (33/141, 23.4%) had not received any treatment because of emotional immaturity or a lack of desire to proceed with therapy at the moment. Among the 141 patients, 14 women (9.9%) had religious beliefs, 103 women (73.0%) had achieved a bachelor’s degree or above, 89 women (63.1%) had a medium to low family income, 111 women (78.7%) were single, and 70 women (49.6%) had sexual partners. Only three (2.1%) had offspring by adoption or surrogacy. In addition, 91 women (64.5%) had a positive self-evaluation of their femininity. A total of 112 patients (79.4%) had plans regarding offspring, of which 53.9% were willing to choose surrogacy.

Analyses of the demographic features showed the age of patients and female controls were comparable while the education level and the family income level were significantly higher in female controls. Thus, the GAD-7 results were compared with age, education level and family income controlled. GAD-7 score was 6.0 (3.5, 9.0) in women with MRKH syndrome while 5.0 (1.0, 7.0) in female controls, which was significantly higher in patient group \( (P = 10.005, P = 0.002) \).

### Incidence and factors associated with anxiety symptoms

Figure 1 displays the incidence of different levels of anxiety symptoms in both groups. Of the patients, 32.6% (46/141) had minimal anxiety symptoms, 43.3% (61/141) had mild symptoms, 16.3% (23/141) had moderate symptoms, and 7.8% (11/141) had severe anxiety symptoms. However, in the healthy group, 49.4% (88/178) had minimal symptoms, 38.8% (69/178) had mild symptoms, only 9.0% (16/178) had moderate symptoms, and 2.8% (5/178) had severe symptoms.

To further explore the factors related to the onset of anxiety symptoms, based on the widely used cut-off score of 10 for the GAD-7, 34 participants (24.1%) were assigned to the anxiety group. Table 2 displays the results of the univariable analysis. In terms of sociodemographic features, married patients were more likely to present anxiety symptoms \( (\chi^2 = 5.256, P = 0.022) \). Regarding the psychological aspects, negative self-evaluation of femininity \( (\chi^2 = 10.685, P = 0.001) \), depressive symptoms \( (\chi^2 = 35.920, P < 0.001) \), introversion \( (t = 3.086, P = 0.004) \), and neurotic \( (t = 8.134, P < 0.001) \) personality traits were more prevalent in the anxiety group. In addition, anxiety status was significantly different among patients with different states of sexual function \( (\chi^2 = 12.826, P = 0.002) \). Compared to patients with normal sexual function and sexually inactive patients, patients with sexual dysfunction were more likely to display anxiety symptoms (Bonferroni-adjusted \( P = 0.015 \), Bonferroni-adjusted \( P = 0.003 \)).
Then, multiple stepwise logistic regression was conducted to screen potential risk factors for anxiety symptoms. We found that women with negative self-evaluations of their femininity (odds ratio [OR] 2.706, 95% confidence interval [CI] 1.010–7.247), coexisting depressive symptoms (OR 4.422, 95% CI 1.498–13.049), and neurotic personality traits (OR 1.100, 95% CI 1.029–1.175) were more likely to exhibit anxiety symptoms [Table 3].

Discussion

As a congenital malformation that results in infertility and an inability to have vaginal intercourse, MRKH syndrome creates a substantial psychological burden that includes anxiety symptoms. Our study found that 24.1% of patients experienced moderate to severe anxiety symptoms, while the figure for healthy women was only 11.8%. Moreover, the GAD-7 scale score was significantly higher in the patient group.

To date, only a few studies have evaluated anxiety symptoms in MRKH patients, and the results have been inconclusive. Liao found that the Hospital Anxiety and Depression Scale scores for anxiety were higher in 58 women with MRKH syndrome than in the reference sample.[18] Another study including only five MRKH patients reached a similar conclusion using the State-Trait Anxiety Inventory.[3] However, another two studies enrolling 66 and 54 MRKH cases, respectively both claimed that the anxiety scores showed no significant difference between the MRKH group and the control group.[19,20] Relatively small sample sizes and the use of various measurement instruments may explain the discrepancy in these results. Based on our findings and a review of previous studies, we note that the severity of anxiety symptoms is increased in patients with MRKH syndrome. With more severe anxiety symptoms, patients with MRKH syndrome are at a higher risk of anxiety disorders. Therefore, for this group of women, anxiety evaluation is of great importance. However, in the busy and complex clinical setting, it is difficult to conduct diagnostic evaluations for anxiety disorders for every patient. Therefore, evaluating anxiety symptoms using a simple measuring tool and referring high-risk patients to psychology professionals is a feasible solution.

Our study showed that negative self-evaluation of femininity, neurotic personality traits and coexisting depressive symptoms are potential risk factors for anxiety symptoms in MRKH patients.

In terms of self-evaluation of femininity, due to the cross-sectional study design, we cannot determine the causal connection between anxiety symptoms and negative evaluation of femininity in MRKH patients. One possible explanation is that the negative evaluation of female identity is anxiety-arousing. Supporting this, a randomized controlled trial of a cognitive-behavioral therapy (CBT) intervention was based on the premise that the core issue of MRKH syndrome was the threat to the patient’s female role; the trial obtained satisfactory improvements in psychological outcomes, including anxiety symptoms, in the CBT intervention group.[19] This psychotherapy targeting the negative evaluation of femininity improved anxiety outcomes, supporting our hypothesis that doubts about female identity are anxiety-arousing and potential treatment targets for MRKH syndrome.

In addition, neurotic personality traits might contribute to anxiety symptoms in MRKH patients. Similar results were also reported previously.[21] It has been hypothesized that the diagnosis of MRKH syndrome in adolescence has an impact on the development of personality traits, which may explain the higher neuroticism level in MRKH patients.[21] Moreover, according to Eysenck’s theory, neurotic people are more prone to emotional instability and negative emotions under the stress of life events. This could partly account for the increased anxiety symptoms in MRKH patients. Therefore, when a woman receives a diagnosis of MRKH syndrome, it is of great importance that she receives a thorough psychological state evaluation, and extra attention should be given to neurotic patients.
Moreover, coexisting depressive symptoms are also associated with increased onset of anxiety symptoms in patients with MRKH syndrome. Many studies have reported that the comorbidity of anxiety and depression is prevalent, which could explain our results to some extent. However, it has also been reported that comorbidity results in more severe psychiatric symptoms, poorer psychosocial functioning, and higher suicide risk.
In conclusions, two-thirds of patients with MRKH syndrome experience anxiety symptoms, and nearly a quarter have moderate to severe symptoms. Moreover, neurotic personality traits, negative self-evaluation of femininity, and coexisting depressive symptoms are potential risk factors of anxiety symptoms in MRKH patients. Hence, anxiety symptom screening is necessary for patients with MRKH syndrome, and psychological counseling and intervention should be considered independent of other treatments intended to correct anatomical abnormalities in these patients.

**Conflicts of interest**

None.

**References**

1. Herlin M, Bjorn AM, Rasmussen M, Trolle B, Petersen MB. Prevalence and patient characteristics of Mayer-Rokitansky–Küster-Hauser syndrome: a nationwide registry-based study. Hum Reprod 2016;31:2384–2390. doi: 10.1093/humrep/dev220.
2. Fontana L, Gentilin B, Fedele L, Gervasini C, Mozzio M. Genetics of Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. Clin Genet 2017;91:233–246. doi: 10.1111/cge.12883.
3. Satterfield JM, Feldman MD. Anxiety. Behavioral Medicine: A Guide for Clinical Practice. Fourth EditionNew York: McGraw-Hill Education; 2014:271–282.
4. Bean EJ, Mazur T, Robinson AD. Mayer-Rokitansky-Küster-Hauser syndrome: sexuality, psychological effects, and quality of life. J Pediatr Adol Gynec 2009;22:339–346. doi: 10.1016/j.jpag.2008.11.006.
5. Lagari V, Diareme S, Chrestogeorgos S, Deligeoroglou E, Christopoulos P, Tsiantis J, et al. Anxiety and depression in adolescents with polycystic ovary syndrome and Mayer-Rokitansky-Küster-Hauser syndrome. J Psychosom Obstet Gynecol 2009;30:83–88. doi: 10.1080/01674820802546204.
6. Heller-Boersma JG, Schmidt Uh, Edmonds DK. A randomized controlled trial of a cognitive-behavioural group intervention versus waiting-list control for women with urovaginal agenesis (Mayer-Rokitansky–Küster-Hauser syndrome: MRKH). Hum Reprod 2007;22:2296–2301. doi: 10.1093/humrep/dem167.
7. Communal P. Sexuality after sigmoid colpopoiesis in patients with Mayer Rokitansky Kuster Hauser syndrome. Fertil Steril 2003;80:600–606. doi: 10.1016/s0015-0282(03)00796-9.
8. Ernst ME, Sandberg DE, Keegan C, Quint EH, Lossie AC, Yashar BM. The lived experience of MRKH: sharing health information with peers. J Pediatr Adolesc Gynecol 2016;29:154–158. doi: 10.1016/j.jpag.2015.09.009.
9. Kroonen K, Spitzer RL, Williams JBW, Monahan PO, Løwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317–325. doi: 10.7326/0003-4819-146-5-200703060-00004.
10. Løwe B, Deckers O, Müller S, Brahler E, Schellberg D, Herzog W, et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care 2008;46:266–274. doi: 10.1097/mlr.0b013e31813160d93.
11. He X, Li C, Qian J, Cui H, Wu W. Reliability and validity of a generalized anxiety disorder scale in general hospital outpatients (in Chinese). Shanghai Arch Psychiatry 2010;22:200–203. doi: 10.3969/j.issn.1002-0829.2010.04.002.
12. Wang W, Bian Q, Zhao Y, Li X, Wang W, Du J, et al. Reliability and validity of the Chinese version of the patient health questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry 2015;37:59–65. doi: 10.1016/j.genhosppsych.2014.05.021.
13. Kroonen K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–613. doi: 10.1046/j.1525-152X.2001.06100906.x.
14. Manza L, Gilbody S, McMillan D. A diagnostic meta-analysis of the patient health questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry 2015;37:67–75. doi: 10.1016/j.genhosppsych.2014.09.009.
15. Qian M, Wu G, Zhu R, Zhang S. A revised version of Eysenck personality questionnaire short form scale Chinese version (EPQ-RSC) (in Chinese). Acta Psychol Sin 2000;32:317–323. doi: CNKI:SUN:XLXB.0.2000-03-014.

16. Zhang C, Tong J, Zhu L, Zhang L, Xu T, Lang J, et al. A population-based epidemiologic study of female sexual dysfunction risk in mainland China: prevalence and predictors. J Sex Med 2017;14:1348–1356. doi: 10.1016/j.jsxm.2017.08.012.

17. Ma J, Pan L, Lei Y, Zhang A, Kan Y. Prevalence of female sexual dysfunction in urban Chinese women based on cutoff scores of the Chinese version of the female sexual function index: a preliminary study. J Sex Med 2014;11:909–919. doi: 10.1111/jsm.12451.

18. Liao L-M, Conway GS, Ismail-Pratt I, Bikoo M, Creighton SM. Emotional and sexual wellness and quality of life in women with Rokitansky syndrome. Am J Obstet Gynecol 2011;205:117.e1–117. e6. doi: 10.1016/j.ajog.2011.03.013.

19. Heller-Boersma JG, Schmidt UH, Keith Edmonds D. Psychological distress in women with uterovaginal agenesis (Mayer-Rokitansky-Küster-Hauser syndrome). Psychosomatics 2009;50:277–281. doi: 10.1176/appi.psy.50.3.277.

20. Weijenborg PTM, Kluivers KB, Dessens AB, Kate-Booij MJ, Both S. Sexual functioning, sexual esteem, genital self-image and psychological and relational functioning in women with Mayer-Rokitansky-Küster-Hauser syndrome: a case-control study. Hum Reprod 2019;34:1661–1673. doi: 10.1093/humrep/dez130.

21. Bargiel-Matusiewicz K, Kroemeke A. Personality traits and coping styles in women with Mayer-Rokitansky-Küster-Hauser syndrome. Arch Med Sci 2015;11:1244–1249. doi: 10.5114/ams.2015.56350.

22. Chen H, Wang X, Huang Y, Li G, Liu Z, Li Y, et al. Prevalence, risk factors and multi-group latent class analysis of lifetime anxiety disorders comorbid depressive symptoms. J Affect Disord 2019;243:360–365. doi: 10.1016/j.jad.2018.09.053.

23. Cyranowski JM, Schott LL, Kravitz HM, Brown C, Thurston RC, Joffe H, et al. Psychosocial features associated with lifetime comorbidity of major depression and anxiety disorders among a community sample of mid-life women: the SWAN mental health study. Depress Anxiety 2012;29:1030–1037. doi: 10.1002/da.21990.

24. Chen T-H, Chang S-P, Tsai C-F, Juang K-D. Prevalence of depressive and anxiety disorders in an assisted reproductive technique clinic. Hum Reprod 2004;19:2313–2318. doi: 10.1093/humrep/deh414.

25. Omani-Samani R, Ghahteri A, Navid B, Sepidarkish M, Maroufizadeh S. Prevalence of generalized anxiety disorder and its related factors among infertile patients in Iran: a cross-sectional study. Health Qual Life Outcomes 2018;16:129. doi: 10.1186/s12955-018-0956-1.

26. Friedler S, Grin L, Liberti G, Saar-Ryss B, Robinson Y, Melitzer S. The reproductive potential of patients with Mayer–Rokitansky–Küster–Hauser syndrome using gestational surrogacy: a systematic review. Reprod Biomed Online 2016;32:54–61. doi: 10.1016/j.rbmo.2015.09.006.

27. Committee on Adolescent Health Care. ACOG committee opinion No. 728: Müllerian agenesis. Obstet Gynecol 2018;131:e35–e42. doi: 10.1097/AOG.0000000000002458.

28. Zhu L, Lang JH, Song L, Luo GN, Huang XH, Wang P, et al. Chinese expert consensus on the diagnosis and treatment of Herlyn-Werner-Wunderlich syndrome, Mayer-Rokitansky-Küster-Hauser syndrome and vaginal atresia (in Chinese). Chin J Obstet Gynecol 2018;53:35–42. doi: 10.3760/cma.j.issn.0529-567X.2018.01.008.

How to cite this article: Song S, Chen N, Duan YP, Kang J, Deng S, Pan HX, Zhu L. Anxiety symptoms in patients with Mayer-Rokitansky-Küster-Hauser syndrome: a cross-sectional study. Chin Med J 2020;133:388–394. doi: 10.1097/CM9.0000000000000648